- A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-b, in patients with advanced nonsmall cell lung cancer (NSCLC)Feng, J.; Shi, M.; Chen, J.; Li, K.; Li, X.; Sun, M.; Li, B.; Wen, G.; Fang, Y.; Min, X.; Lin, L.; Liu, Y.; Wang, Q.; Lu, S.; Zhu, B.; Shi, Y-K.; Yu, H.; Peng, Y.; Liang, F.; Liu, P.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-?, in patients with advanced tumorsGuo, Ye; Liu, Baogang; Lv, Dongqing; Cheng, Ying; Zhou, Tong; Zhong, Yahua; Hu, Changlu; Chen, Gang; Wu, Xiaohua; Yin, Yongmei; Wu, Lihua; Chen, Zhendong; Luo, Hong; Zhou, Xiaohong; Qin, Yanru; Yang, Yuxing; Luo, Suxia; Ma, Yanjie; Li, Yalin; Hu, GuoqiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 5
- SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III studyXu, R-H.; Qiu, M.; Bai, Y.; Wang, J.; Gu, K.; Yang, M.; He, Y.; Yi, C.; Jin, Y.; Liu, B.; Wang, F.; Huang, C.; Jiang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/ TGF-bRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
8阅读
